Wednesday, May 4, 2005
South San Francisco, Calif. -- May 4, 2005 --Genentech, Inc. (NYSE:DNA) today announced three vice president appointments in the company's Product Operations and Product Development groups: the promotion of Charles Calderaro to vice president, Corporate Engineering; the appointment of Peter Carberry, M.D., to vice president, Clinical Operations; and the promotion of Todd Rich, M.D., to vice president, Clinical and Commercial Regulatory Affairs.
Chuck Calderaro, 41, joined Genentech in 2002 as senior director, Biochemical Manufacturing at the company's Vacaville Product Operations facility.
In his new role as vice president, Corporate Engineering, Calderaro will be based in South San Francisco and will lead the development and implementation of engineering projects that support Genentech's growth, including the development of compliant and robust systems, equipment and facilities. Calderaro reports to Patrick Y. Yang, Ph.D., senior vice president, Product Operations and succeeds Timothy L. Moore, who was named vice president, South San Francisco Manufacturing in December 2004 and served as vice president, Corporate Engineering on an interim basis. Moore continues his role as vice president, South San Francisco Manufacturing.
"Chuck's solid leadership skills and hands-on experience in Engineering, Facilities and Operations make him ideally suited to effecting a strong partnership between Corporate Engineering and the rest of the company in support of our growth," said Yang.
Prior to joining Genentech, Calderaro held leadership roles at Aventis Behring, including director, Biopharmaceutical Manufacturing and, most recently, director, Engineering and Facility Services. Calderaro has also held positions at Alcon Laboratories and Johnson & Johnson's Ethicon division. Calderaro served five years as a Commissioned Naval Officer with the U.S. Navy.
Calderaro holds a Bachelor of Science in Electrical Engineering from the University of Notre Dame, a Master of Science in Nuclear Engineering from the U.S. Naval Nuclear Power School in Orlando, and a Master of Business Administration from Texas Christian University.
Peter Carberry, M.D.
Peter Carberry, M.D., 47, joins Genentech as vice president, Clinical Operations and in this newly created role will be responsible for clinical operational guidance and ensuring the effective execution of all clinical programs. Additionally, he will build and develop the Clinical Operations group, responsible for the creation and sustainability of scalable business processes for clinical trial execution. Carberry reports to Hal Barron, M.D., senior vice president, Development and Chief Medical Officer.
"Peter has a proven track record of successfully managing teams of clinical research professionals and effectively executing clinical trials in the United States as well as globally," said Barron.
Carberry joins Genentech from Johnson & Johnson Pharmaceutical Research and Development, where he served as the senior vice president of Global Operations. Carberry also held several leadership roles in Clinical Development, Corporate Pharmacovigilance and Global Clinical Operations at Pharmacia Corporation.
Carberry holds his Bachelor of Medicine and his Bachelor of Surgery from the University of Nairobi, Kenya and also attended its Master of Medicine in Surgery program. Carberry completed his postdoctoral fellowship in Clinical Pharmacology at the University of Texas, San Antonio. Carberry received his Master of Business Administration from Western Michigan University.
Todd Rich, M.D.
Clinical and Commercial Regulatory Affairs
Todd Rich, M.D., 49, joined Genentech in 1992 as manager, New Product Planning. In 1993, he became senior manager of the newly created Health Economics group. During the next several years, he held positions as director, Product Experience; senior director, Product Development; and, most recently, senior director, Regulatory Affairs.
In the newly created role of vice president, Clinical and Commercial Regulatory Affairs, Rich will be responsible for the regulatory direction of both the Development and Commercial teams, overseeing the regulatory strategy for clinical trials, the management of commercial advertising and promotional materials, and all Food and Drug Administration clinical trial post-marketing commitments. Rich reports to Robert L. Garnick, Ph.D., senior vice president, Regulatory, Quality and Compliance.
"Todd brings to this critical new position strong leadership skills and strategic ability as well as extensive experience in Medical Affairs, Product Development and Regulatory Affairs," said Garnick.
Prior to joining Genentech, Rich was a staff physician in a Level I Trauma Center at St. John Hospital in Detroit.
Rich received his Bachelor of Science in Biology from Amherst College, his Master of Science in Biomedical Engineering from University of Michigan, Ann Arbor, and his medical degree from Wayne State University. Rich also holds his Master of Business Administration, with a concentration in Marketing, from Stanford University's Graduate School of Business.
Genentech is a leading biotechnology company that discovers, develops, manufactures, and commercializes biotherapeutics for significant unmet medical needs. A considerable number of the currently approved biotechnology products originated from, or are based on, Genentech science. Genentech manufactures and commercializes multiple biotechnology products directly in the United States, and receives royalties or other income from companies that are licensed to market its products outside of the United States. The company has headquarters in South San Francisco, Calif., and is traded on the New York Stock Exchange under the symbol DNA. For additional information about the company, please visit http://www.gene.com.